Blueprint Medicines (BPMC) Misses Q3 EPS by 5c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.96), $0.05 worse than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c